The stock is listed on the Nasdaq Global Market

Davis Polk advised the joint book-running managers in connection with an upsized $150 million SEC-registered common stock and pre-funded warrants offering by TScan Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “TCRX.”

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The company is also developing multiplexed TCR-T candidates for the treatment of various solid tumors.

The Davis Polk corporate team included partner Marcel Fausten and associates Robert MacKenzie and Jenny Li. The tax team included partner Kara L. Mungovan and associates Dov Sussman and Albert Park. The intellectual property team included partner David R. Bauer and associate Gabrielle Mazero. All members of the Davis Polk team are based in the New York office.